A flood of new state laws now strictly regulates pharmaceutical and medical device companies' interactions with healthcare professionals, and more are on the way. Unlike the Pharmaceutical Research and Manufacturers of America and AdvaMed codes on interactions with healthcare professionals, which are voluntary, these state laws include fines and penalties for noncompliance. And now Congress is considering the Physician Payments Sunshine Act of 2009, which would also require that aggregate ...

Register for Complete Access (Valid Email Required)

By registering on MeetingsNet now, you'll not only gain access to How New State Pharma Marketing Laws Could Affect Continuing Medical Education, you'll get exclusive access to a large archive of premium content.

Already registered? here.